Bayer Wins Second Roundup Cancer Case in California
December 10 2021 - 02:00AM
Dow Jones News
By Ed Frankl
Bayer AG said Thursday that a jury in California found that its
weedkiller Roundup wasn't the cause of a woman's cancer.
The result is the second trial victory the German
pharmaceutical-and-chemical conglomerate has had for its glyphosate
pesticide, after a jury in Los Angeles ruled in Bayer's favor for
the first time in October. Bayer lost its first three cases
involving Roundup.
The court in San Bernardino found in favor of the company, after
Donetta Stephens said she got non-Hodgkin's lymphoma after having
used Roundup herbicide for more than 30 years.
"The jury's verdict in favor of the company brings this trial to
a successful conclusion and is consistent with the evidence in this
case that Roundup isn't the cause of Ms. Stephens' cancer. While we
have great sympathy for Ms. Stephens, we agree with the jury that
Roundup isn't the cause of her illness," a Bayer spokesperson
said.
Bayer maintains that Roundup, which it acquired when it bought
agrochemical company Monsanto for $63 billion, doesn't cause
cancer.
The Leverkusen, Germany-based company hopes a ruling by the U.S.
Supreme Court in a separate case will help put to rest yearslong
litigation over the weedkiller.
"The company continues to stand behind the safety of Roundup and
will confidently defend the safety of our product as well as our
good faith actions in any future litigation," Bayer said.
Legal issues surrounding Roundup have prompted the company to
set aside billions in provisions to settle cases.
Write to Ed Frankl at edward.frankl@dowjones.com
-0-
(END) Dow Jones Newswires
December 10, 2021 01:45 ET (06:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2023 to Mar 2024